1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Osteoporosis Drugs Market in BRIC Nations 2015-2019

Osteoporosis Drugs Market in BRIC Nations 2015-2019

  • September 2015
  • -
  • Infiniti Research Limited
  • -
  • 68 pages

About osteoporosis
Osteoporosis, or porous bone, is a disease characterised by low bone density and structural deterioration of bone tissue, leading to fragile bones. This increases the risk of fractures. Osteoporosis mainly affects women, but can also affect men. In women, bone loss occurs very rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement occurs too slowly. Risk factors for osteoporosis that cannot be controlled include gender, age, body size (low body weight), ethnicity, and family history. Risk factors that can be controlled include sex hormones, medication use, calcium and vitamin intake, alcohol intake, and smoking.

Technavio's analysts forecast the osteoporosis drugs market in BRIC nations to grow at a CAGR of 17.43% over the period 2014-2019.

Covered in this report
This report covers the present scenario and the growth prospects of the osteoporosis drugs market in BRIC nations for the period 2015–2019. To calculate the market size, the report considers revenue generated from the sales of various pharmaceutical products used in the treatment of osteoporosis. Pharmaceutical products are classified as branded and generic drugs.

Technavio's report, Osteoporosis Drugs Market in BRIC Nations 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Brazil, Russia, India, and China; it also covers the landscape of the osteoporosis drugs market in BRIC nations and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

Key countries
- Brazil
- China
- India
- Russia

Key Vendors
- Amgen
- Eli Lilly
- Merck
- Novartis

Other prominent vendors
- Abiogen Pharma
- Deltanoid Pharmaceuticals
- F. Hoffmann La Roche
- GlaxoSmithKline
- IMMD
- Ligand Pharmaceuticals
- Pantarhei Bioscience
- Pfizer
- PhytoHealth
- Radius Health
- UPSHER-SMITH LABORATORIES
- Zosano Pharma

Market driver
- Increase in aging population
- For a full, detailed list, view our report

Market challenge
- Multiple patent expiries
- For a full, detailed list, view our report

Market trend
- Shift toward anabolic treatments
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Osteoporosis Drugs Market in BRIC Nations 2015-2019
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Osteoporosis: An overview
Understanding osteoporosis
Epidemiology and demography
Risk factors
Symptoms
Diagnosis
Treatment
PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 07: Pipeline Assessment
Key information of pipeline candidates
PART 08: Market segmentation by therapeutic class
Antiresorptive medication
Anabolic medication
PART 09: Market segmentation by line of therapy
PART 10: Geographical segmentation
PART 11: Country overview
China
India
Russia
Brazil
PART 12: Market drivers
Rise in aging population
Emergence of novel agents
High unmet medical needs
Increased incidence of osteoporosis
PART 13: Impact of drivers
PART 14: Market challenges
Expiry of patents
Limited access to diagnostic tools
Poor patient compliance
Inadequate reimbursement policies
Lack of public awareness
PART 15: Impact of drivers and challenges
PART 16: Market trends
Shift toward anabolic treatment
Use of combination therapies
Increased awareness of bone health education
PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 18: Key vendor analysis
Amgen
Eli Lilly
Merck
Novartis
PART 19: Appendix
List of abbreviations
PART 20: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Incidence of osteoporosis-related hip fractures 2012
Exhibit 03: Interpretation of BMD results
Exhibit 04: Osteoporosis drugs market in BRIC 2014-2019 ($ billions)
Exhibit 05: Five forces analysis
Exhibit 06: Product pipeline
Exhibit 07: Segmentation of osteoporosis drugs market in BRIC by therapeutic class
Exhibit 08: Segmentation of osteoporosis drugs market in BRIC by line of therapy
Exhibit 09: Segmentation of osteoporosis drugs market in BRIC by geography 2014
Exhibit 10: Key countries
Exhibit 11: Life expectancy in China (age in years)
Exhibit 12: Population projection of China (millions)
Exhibit 13: Percentage of urban and rural population in China 2013
Exhibit 14: Life expectancy in India (age in years)
Exhibit 15: Population projection of India (millions)
Exhibit 16: Percentage of urban and rural population in India 2013
Exhibit 17: Population projection of people aged 50 and above in Russia 2011 and 2050 (millions)
Exhibit 18: Population projection of Brazil 2011 and 2050 (millions)
Exhibit 19: Life expectancy in Brazil 2010 and 2050 (age in years)
Exhibit 20: Estimated population aged 60 and above in BRIC countries 2010-2013
Exhibit 21: Impact of drivers
Exhibit 22: Impact of drivers and challenges
Exhibit 23: Eli Lilly: YoY growth and revenue of Evista 2010-2014 ($ millions)
Exhibit 24: Eli Lilly: YoY growth and revenue of Forteo 2010-2014 ($ millions)
Exhibit 25: Amgen: YoY growth and revenue of Prolia 2010-2014 ($ millions)
Exhibit 26: Merck: YoY growth and revenue of Fosamax 2011-2014 ($ millions)
Exhibit 27: Novartis: YoY growth and revenue of Reclast/Aclasta 2010-2013 ($ millions)
Exhibit 28: Amgen: Business segmentation by revenue 2014
Exhibit 29: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 30: Amgen: Geographical segmentation by revenue 2014
Exhibit 31: Business segmentation by revenue 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Global Markets for Diabetes Therapeutics and Diagnostics

Global Markets for Diabetes Therapeutics and Diagnostics

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Analyze the market for drugs used in the treatment of diabetes, it's technology and the industry as a whole - Identify important trends and provide sales forecasts by product categories ...

Personal Mobility Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Personal Mobility Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Personal mobility devices such as wheelchairs, mobility scooters, and stair lifts have witnessed significant growth in revenue and volume in the past few years. A personal mobility device is either a manual ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.